Biobeat receives CE mark for AI-powered remote monitoring platform

Biobeat, a wearable remote patient monitoring player has received the CE mark for its full AI-powered wearable remote patient monitoring platform.

The approval encompasses Biobeat’s wrist and chest-patch monitoring devices’ continuous monitoring of crucial patient vital signs, including blood oxygen saturation, respiratory rate, non-invasive cuffless blood pressure, pulse rate, pulse rate variability, mean arterial pressure, pulse pressure, stroke volume, cardiac output, cardiac index, systemic vascular resistance and skin temperature. 

It also includes one-lead EKG for the chest monitor device. The approval also comprises Biobeat’s wireless capabilities, which include its proprietary Gateway (hospital) connectivity tool, Mobile App (home), and cloud-based web management platform for healthcare providers, which provide healthcare staff with a continuous, scalable view of patient health and predictive patient deterioration alerts.

Arik Ben Ishay, CEO of Biobeat, said: “We are proud to receive CE mark for the full gamut of remote patient monitoring capabilities that our wearable wrist and chest monitors and AI-enabled patient management tools can provide. With this approval, we further our goal of improving care and elevating patient outcomes across the European healthcare continuum, which now includes the new care frontier: the home.”

Biobeat’s wearable patient monitoring devices utilise non-invasive reflective photoplethysmography technology to automatically and continuously track 15 cardio-pulmonary vital signs. The wireless solutions connect to a cloud-based patient management system to provide medical staff with real-time data and alerts, enabling early identification of clinical deterioration. The management platform includes an integrated automated, customisable early warning score system that incorporates advanced health-AI-based algorithms that analyse aggregated patient data to identify deterioration more accurately and provide predictive analytics.

Biobeat’s hospital and long-term care monitoring solutions are currently used in dozens of medical centres and facilities across the globe.

Dr. Dan J. Gelvan, chairman of the Biobeat advisory board, said: “With the current growing need for accurate remote patient monitoring technologies, we are excited to receive this approval and cement our status as a leading provider of wearable monitoring devices and scalable patient management systems for both hospital and home use.”